Fact-checked by Grok 2 weeks ago

HBsAg

HBsAg, or hepatitis B surface antigen, is the principal protein found on the outer surface of the hepatitis B virus (HBV), functioning as a critical serological marker for identifying active HBV infection in individuals.^[1] It appears in the blood as the first detectable antigen, typically 1 to 9 weeks following initial exposure to the virus, and its presence signifies either acute or chronic infection, with high serum levels indicating ongoing viral replication and potential transmissibility.^[2]^[3] Detection of HBsAg is essential for routine screening, particularly in at-risk populations such as adults aged 18 and older, pregnant individuals, and those with elevated liver enzymes, enabling early diagnosis and intervention to prevent liver damage.^[1] Furthermore, HBsAg serves as the key immunogenic component in the hepatitis B vaccine, stimulating the production of protective anti-HBs antibodies that confer immunity against HBV.^[1] Structurally, HBsAg is a multifunctional glycoprotein assembled from three isoforms: the large (LHB), middle (MHB), and small (SHB) hepatitis B surface proteins, which form subviral particles secreted by infected hepatocytes even in the absence of complete virions.^[4] These isoforms contribute to the antigen's role in immune evasion and viral persistence, with variations in their expression influencing clinical outcomes such as the likelihood of chronicity or response to antiviral therapies.^[4] Quantitatively, HBsAg levels correlate with viral load and disease phase; elevated titers often reflect high infectivity in acute cases, while declining levels may signal resolution or effective treatment in chronic hepatitis B.^[5] In clinical practice, HBsAg testing is performed via enzyme immunoassays and is interpreted alongside other markers like anti-HBc and HBeAg to distinguish infection stages and guide management, including vaccination, antiviral prophylaxis, and monitoring for hepatocellular carcinoma risk in chronic carriers.^[2]^[6] Its transient detection post-vaccination (up to 30 days) underscores the need for confirmatory testing to differentiate immune response from true infection.^[1] Overall, HBsAg remains a cornerstone of HBV control strategies worldwide, supporting global efforts to reduce the estimated 254 million chronic cases and associated morbidity as of 2022.^[7]

Biological Properties

Molecular Structure

HBsAg, or hepatitis B surface antigen, is a 22 nm lipoprotein particle primarily composed of the major surface protein (HBs), a 226-amino-acid polypeptide encoded by the S open reading frame of the hepatitis B virus (HBV) genome.^[8] This protein forms the structural backbone of the particle, spanning the lipid bilayer approximately four times to create a micelle-like envelope.^[9] HBsAg exhibits antigenic heterogeneity, classified into major subtypes such as adw, ayw, adr, and ayr, determined by specific epitopes within the major hydrophilic region (MHR) of the S protein, including the common 'a' determinant and subtype-specific markers like 'd/y' and 'w/r'.^[10] These subtypes arise from single nucleotide polymorphisms in the S gene, influencing immunological recognition without altering the overall particle architecture.^[11] As a glycoprotein, HBsAg incorporates host-derived lipids, comprising approximately 25-40% of its mass by weight, which form a phospholipid monolayer surrounding the protein core.^[9]^[12] The lipid composition includes cholesterol, phospholipids, and sphingolipids, contributing to the particle's stability and buoyancy in serum.^[13] Glycosylation occurs primarily at an N-linked site at asparagine 146 (N146) within the MHR's antigenic loop, a conserved motif across HBV genotypes that modulates protein folding and secretion; additional sites in the pre-S regions, such as N4 in pre-S2 for certain genotypes, further diversify its post-translational modifications.^[14]^[15] In circulation, HBsAg assembles into non-infectious subviral particles (SVPs), predominantly 22 nm spherical forms or elongated filaments up to 400 nm in length, which vastly outnumber the 42 nm infectious Dane particles (complete virions).^[16] These SVPs form through self-assembly of HBs proteins in the endoplasmic reticulum of infected hepatocytes, driven by hydrophobic interactions and disulfide bonds, resulting in D2- and D4-like quasisymmetry in spherical variants, consisting of 40 or 48 copies of HBsAg dimers.^[17] Unlike Dane particles, which enclose the viral nucleocapsid, HBsAg SVPs lack genomic DNA and serve as decoys in host immune evasion.^[18] Genetic variations in the S gene can introduce mutations that alter HBsAg structure, particularly in the MHR, leading to immune escape mutants that disrupt epitope conformation while preserving particle integrity.^[19] Common escape mutations, such as G145R or P120T, involve single amino acid substitutions that reduce antibody binding affinity by altering the antigenic loop's flexibility or surface exposure, often selected under vaccine or antiviral pressure.^[20] These variants maintain the lipoprotein scaffold but may influence assembly efficiency or glycosylation patterns, contributing to diagnostic challenges.^[21]

Biological Function

HBsAg, the surface antigen of the hepatitis B virus (HBV), plays a critical role in forming the viral envelope that envelops the nucleocapsid during virion assembly.^[18] This glycoprotein, particularly its large isoform containing the preS1 domain, facilitates the initial attachment of HBV to hepatocytes by binding to the sodium taurocholate cotransporting polypeptide (NTCP) receptor on the cell surface, initiating viral entry through endocytosis.^[22] As glycoprotein particles composed primarily of the small HBsAg isoform, they embed within a lipid bilayer derived from host membranes, enabling the mature virion to exit infected cells via multivesicular body pathways.^[18] During HBV infection, hepatocytes produce HBsAg in vast excess relative to complete virions, resulting in the secretion of non-infectious subviral particles (SVPs) that vastly outnumber infectious particles by 1,000- to 100,000-fold.^[23] These spherical or filamentous SVPs, consisting solely of HBsAg and host lipids without viral genome or capsid, act as decoys that divert the host immune response, particularly by binding and neutralizing anti-HBs antibodies before they can target actual virions.^[24] This overproduction contributes to the persistence of chronic infection by overwhelming humoral immunity and reducing the efficacy of B cell responses.^[25] HBsAg further promotes immune evasion by suppressing both innate and adaptive responses, including the impairment of HBV-specific T and B cell functions through direct interactions that induce tolerance.^[26] High circulating levels of HBsAg, often reaching hundreds of micrograms per milliliter in chronic hepatitis B (CHB), inhibit cytokine production such as IL-12 and hinder Th1-mediated antiviral activity, facilitating viral persistence without overt hepatocyte damage.^[27] Additionally, HBsAg modulates host lipid metabolism by associating with cholesterol-rich membrane rafts, which are essential for its secretion and the stability of both virions and SVPs; depletion of cholesterol disrupts these processes and reduces particle release.^[28]

Detection and Assay

Immunoassay Methods

Immunoassay methods for detecting hepatitis B surface antigen (HBsAg) primarily utilize antibody-based techniques to identify and quantify the antigen in biological samples such as serum or plasma. These methods leverage the specific binding of antibodies to HBsAg epitopes, enabling high sensitivity and specificity in laboratory settings. The choice of method depends on the required throughput, turnaround time, and detection limits, with established protocols ensuring reliable results for screening and diagnosis. The enzyme-linked immunosorbent assay (ELISA) remains the gold standard for HBsAg detection due to its high sensitivity and ability to process large sample volumes. In the direct sandwich format, monoclonal antibodies specific to HBsAg are immobilized on a solid phase to capture the antigen from the sample; a second enzyme-conjugated monoclonal antibody then binds to a different epitope on the captured HBsAg, producing a colorimetric signal proportional to antigen concentration upon substrate addition. Indirect formats, while less common for routine HBsAg screening, involve an unlabeled detection antibody followed by an enzyme-linked secondary antibody, offering flexibility for research applications where amplification of the signal is beneficial. These ELISA variants commonly employ monoclonal antibodies targeting the conserved 'a' determinant of HBsAg to ensure broad subtype coverage.^[29]^[30] For point-of-care applications, rapid immunochromatographic tests (ICTs) provide a simple, lateral-flow-based alternative that requires minimal equipment and delivers results in 15-20 minutes. These tests use nitrocellulose strips impregnated with monoclonal capture antibodies; as the sample migrates, HBsAg binds to labeled detector antibodies, forming a visible line if present, with built-in controls for validity. ICTs typically achieve analytical sensitivities of approximately 10 ng/mL, making them suitable for resource-limited settings, though they may require confirmatory ELISA for equivocal results.^[31]^[32] In scenarios involving HBsAg escape mutants or occult hepatitis B virus (HBV) infections where antigen levels are undetectable by immunoassays, polymerase chain reaction (PCR)-based enhancements offer superior sensitivity for low-level detection. Real-time PCR amplifies HBV DNA sequences encoding HBsAg, allowing indirect quantification and genotyping of mutants that alter antigenic sites, with detection limits as low as 10-100 IU/mL of HBV DNA. These molecular methods complement immunoassays by identifying persistent infection in HBsAg-negative individuals.^[33]^[34] Quality control in HBsAg immunoassays is standardized using World Health Organization (WHO) reference panels, which include calibrated standards for various HBV genotypes and subtypes to validate assay performance. These panels, such as the WHO International Standard for HBsAg (genotype A2), enable harmonization of sensitivity across commercial kits, ensuring detection thresholds below 0.1 IU/mL and minimizing inter-laboratory variability. Regular use of these reagents in proficiency testing supports regulatory compliance and reliability in global surveillance.^[35]^[36]

Serological Interpretation

The presence of hepatitis B surface antigen (HBsAg) in serum is the primary serological marker for active hepatitis B virus (HBV) infection, indicating either acute or chronic infection depending on its duration and other markers.^[1] In acute HBV infection, HBsAg typically appears 1 to 10 weeks after exposure and becomes detectable before symptoms or liver enzyme elevations, remaining positive for a variable period but usually clearing within 1 to 6 months as the immune response resolves the infection.^[37] In contrast, persistence of HBsAg beyond 6 months defines chronic HBV infection, often confirmed by the absence of immunoglobulin M (IgM) antibody to hepatitis B core antigen (anti-HBc IgM), which distinguishes it from recent acute cases where IgM anti-HBc is positive.^[1]^[38] Quantitative assessment of HBsAg levels provides additional insight into viral replication and disease phase, correlating with HBV DNA viral load in many cases, though the relationship varies by infection stage and genotype. Levels exceeding 100,000 IU/mL are often observed in the immune-tolerant phase of chronic infection, characterized by high viral replication and minimal liver damage.^[39] Lower levels, such as below 1,000 IU/mL, may indicate immune control or inactive carrier states with reduced infectivity, while intermediate levels (e.g., 1,000–10,000 IU/mL) can reflect immune clearance phases with ongoing replication.^[5] These quantitative thresholds help gauge infectivity risk, as higher HBsAg concentrations generally align with elevated HBV DNA, though discrepancies occur in HBeAg-negative chronic cases due to viral mutations.^[40] Interpretation of HBsAg must account for its distinction from protective markers like antibody to HBsAg (anti-HBs), which signals resolved infection or vaccine-induced immunity and is mutually exclusive with detectable HBsAg in most scenarios. Coexistence of HBsAg and anti-HBs is rare and typically transient during seroconversion.^[1]^[37] Several factors can complicate HBsAg-based assessment, including the window period shortly after infection when HBsAg may be transiently negative despite active viremia, necessitating total anti-HBc testing for detection. Additionally, occult HBV infection poses a diagnostic challenge, defined by undetectable HBsAg but persistent HBV DNA in serum or liver, often with isolated anti-HBc positivity; this state carries low but nonzero transmission risk and requires HBV DNA quantification for confirmation.^[41]

Clinical and Research Applications

Diagnostic Uses

HBsAg testing serves as a cornerstone for screening blood donations to prevent hepatitis B virus (HBV) transmission through transfusion, a practice recommended by the World Health Organization (WHO) for ensuring the safety of blood supplies globally.^[42] This universal screening identifies HBsAg-positive donors, allowing for the discard of infectious units and reducing the risk of iatrogenic HBV spread, which was a significant concern in the mid-20th century before routine testing. Although as of 2025, the FDA proposes discontinuing HBsAg testing for whole blood donations in favor of HBV DNA nucleic acid testing (NAT), while recommending it for source plasma and maintaining WHO's global endorsement.^[43]^[7] In clinical diagnosis, HBsAg detection confirms active HBV infection, with its persistence for more than six months distinguishing chronic from acute infection according to guidelines from the Centers for Disease Control and Prevention (CDC) and the European Association for the Study of the Liver (EASL).^[1]^[44] Prenatally, universal HBsAg screening of pregnant women is recommended by WHO to identify carriers at high risk of vertical transmission, enabling timely interventions such as antiviral prophylaxis from the 28th week of gestation and newborn immunization to interrupt mother-to-child transmission.^[45] This approach has substantially lowered perinatal HBV rates in high-prevalence areas. During antiviral therapy, such as with tenofovir disoproxil fumarate (TDF), serial HBsAg monitoring assesses treatment response, where HBsAg loss—defined as seroclearance with undetectable HBV DNA sustained for at least six months post-discontinuation—signifies a functional cure and reduced risk of liver complications.^[46] Rates of HBsAg loss with long-term TDF remain low at under 0.5% annually, but it remains a key endpoint in chronic HBV management.^[47] HBsAg testing is routinely integrated with HBV DNA quantification in diagnostic protocols to provide comprehensive HBV profiling, enabling accurate phase classification (e.g., immune-tolerant vs. immune-active) and guiding treatment eligibility beyond serological markers alone.^[48] This combined approach addresses limitations of HBsAg alone, such as in occult infections, and supports ongoing monitoring per AASLD and EASL recommendations.^[44]

Role in Vaccination and Therapy

Recombinant hepatitis B surface antigen (HBsAg) serves as the primary immunogen in modern hepatitis B vaccines, which are produced through recombinant expression in yeast cells, such as Saccharomyces cerevisiae.^[49] These vaccines, including Recombivax HB, consist of purified HBsAg particles that mimic the viral subviral envelope, eliciting a robust humoral immune response that generates neutralizing anti-HBs antibodies in over 90-95% of healthy recipients following a standard three-dose regimen.^[50] This antibody production confers protection against hepatitis B virus (HBV) infection by preventing HBsAg attachment to hepatocytes, thereby blocking viral entry and subsequent replication.^[51] In therapeutic contexts, HBsAg clearance represents a critical endpoint for achieving functional cure in chronic HBV infection, surpassing mere viral suppression as it indicates loss of circulating viral antigens and potential immune control.^[46] Nucleoside analogs, such as entecavir and tenofovir, primarily suppress HBV DNA replication but achieve HBsAg seroclearance in only 1-3% of patients annually, often requiring long-term therapy.^[52] In contrast, pegylated interferon (PEG-IFN) therapy promotes higher rates of HBsAg clearance, up to 10% in select cohorts, by enhancing innate and adaptive immune responses that target infected cells.^[53] Combination strategies, such as PEG-IFN added to nucleoside analogs, further improve outcomes, with HBsAg loss observed in 4-50% of patients depending on baseline viral load and genotype.^[54] Vaccine efficacy can be compromised by HBsAg escape mutants, which arise from mutations in the major hydrophilic region of HBsAg, particularly the 'a' determinant, allowing the virus to evade anti-HBs neutralization.^[55] These mutants, often linked to immune pressure from vaccination or natural infection, exhibit reduced binding to vaccine-induced antibodies, leading to breakthrough infections despite seroprotective anti-HBs levels.^[56] Genotype-specific responses exacerbate this challenge, as HBV genotypes A through H vary in antigenic epitopes; for instance, genotype D mutants are more prevalent in certain regions and show diminished cross-protection from standard vaccines.^[57] Emerging therapies target HBsAg production directly to enhance clearance rates beyond conventional treatments. Small interfering RNA (siRNA) agents, such as ARC-520, silence HBV gene expression by degrading viral transcripts, resulting in profound and dose-dependent reductions in serum HBsAg levels—up to 1.4-3.0 log IU/mL in preclinical and early clinical trials.^[58] In phase II studies, ARC-520 combined with entecavir achieved sustained HBsAg suppression in HBeAg-negative patients, with some maintaining reductions for months post-treatment, though trials were discontinued due to formulation issues; subsequent siRNA iterations continue to explore this approach for functional cure. As of 2025, newer siRNA therapeutics like bepirovirsen have advanced to phase 3 trials, achieving HBsAg seroclearance in up to 9-25% of patients in interim results when combined with nucleoside analogs.^[59]^[60]

Historical Development

Discovery and Isolation

In 1963, Baruch S. Blumberg and his team at the Fox Chase Cancer Center identified an unusual precipitin in the serum of an Australian Aborigine while investigating genetic variations in serum proteins among diverse populations. This antigen, dubbed the "Australia antigen" due to its initial detection in an indigenous Australian donor, was characterized through agar gel diffusion assays and found to be immunologically distinct from known human serum proteins. Subsequent studies revealed its presence in individuals with chronic conditions, including Down syndrome and leukemia, suggesting a possible link to infectious or polymorphic traits.^[61]^[62] By 1967, Blumberg's group established a critical association between the Australia antigen and viral hepatitis, particularly serum hepatitis (now known as hepatitis B), through serological surveys of transfusion-associated cases and hemophiliacs. The antigen was detected in up to 20-30% of acute hepatitis patients but rarely in infectious hepatitis (hepatitis A), indicating specificity for a distinct etiological agent. This epidemiological evidence marked a pivotal shift, positioning the antigen as a marker for hepatitis B transmission rather than a mere polymorphism. In 1969, June D. Almeida employed immune electron microscopy to isolate and visualize the antigen, revealing 20-nm spherical particles and tubular forms in antigen-positive sera, providing the first direct morphological link to a viral structure and confirming its presence in immune complexes during acute infection.^[63] Early efforts to purify the Australia antigen relied on density gradient centrifugation, notably cesium chloride (CsCl) isopycnic banding, which separated the particles at a buoyant density of 1.21-1.23 g/cm³—characteristic of lipoproteins. These methods, developed in the late 1960s and refined by 1971, involved initial precipitation with ethanol or polyethylene glycol followed by ultracentrifugation, yielding highly enriched preparations free from serum contaminants and confirming the antigen's lipoprotein composition through lipid extraction and electrophoretic analysis. Such techniques enabled biochemical characterization, revealing the antigen's protein core enveloped in a lipid bilayer, distinct from typical viral capsids.^[64] Blumberg's contributions culminated in the 1976 Nobel Prize in Physiology or Medicine, awarded for discovering the Australia antigen and elucidating its role in hepatitis B transmission, which revolutionized blood screening and prevention strategies.

Key Advancements

In the late 1970s, the cloning of the hepatitis B virus (HBV) genome facilitated the production of recombinant hepatitis B surface antigen (HBsAg) for vaccine development, marking a significant shift toward safer immunization strategies without reliance on plasma-derived antigens. Researchers successfully expressed the HBV S gene in yeast cells, such as Saccharomyces cerevisiae, enabling the assembly of HBsAg particles that elicited protective antibodies in preclinical models.^[65] This recombinant approach culminated in the licensure of the first yeast-derived HBsAg vaccine in 1986, which demonstrated high immunogenicity and safety in clinical trials, revolutionizing global hepatitis B prevention efforts. During the 1990s, advances in DNA sequencing revealed HBsAg mutants that could evade detection by commercial assays and vaccine-induced immunity, prompting refinements in diagnostic and vaccination protocols. The G145R mutation in the "a" determinant of HBsAg was first identified in a vaccinated child who developed breakthrough infection, highlighting how point mutations alter antigenicity and allow viral persistence despite maternal vaccination.^[66] Subsequent sequencing studies confirmed the stability and transmissibility of such mutants, including intrafamilial spread, which underscored the need for broader surveillance and updated assays to detect variant strains.^[67] The 2000s saw the development of quantitative HBsAg assays, which provided insights into viral replication dynamics by correlating serum levels with intrahepatic covalently closed circular DNA (cccDNA), a key marker of HBV persistence. These assays, often based on chemiluminescent microparticle immunoassays, enabled monitoring of HBsAg titers as low as 0.05 IU/mL and revealed strong positive correlations (r > 0.7) between HBsAg and cccDNA in HBeAg-positive patients, aiding in the assessment of treatment responses.^[68] This quantitative approach shifted clinical management from qualitative detection to dynamic evaluation of viral control, particularly during nucleoside analog therapy where HBsAg decline predicted sustained virological suppression.^[69] In the 2020s, CRISPR-based technologies have emerged as promising tools for targeting HBsAg secretion, offering potential pathways to functional cure by disrupting viral gene expression and protein release. Genome editing with CRISPR/Cas13b has demonstrated up to 87% reduction in secreted HBsAg in cell lines by specifically degrading HBV pregenomic and subgenomic RNAs, including those encoding HBsAg, without off-target effects on host transcripts.^[70] These studies, often delivered via lipid nanoparticles, highlight CRISPR's role in silencing HBsAg production at the transcriptional level, complementing existing therapies and addressing cccDNA-mediated persistence in preclinical models. As of 2025, early clinical trials with CRISPR-based editors, such as ARCUS and PBGENE-HBV, have shown HBsAg reductions of up to 69% and durable ~50% decreases in patients, respectively, indicating progress toward clinical application.^[71]^[72]

References

[1]
Clinical Testing and Diagnosis for Hepatitis B - CDC
Jan 31, 2025 · HBsAg is the antigen used to make HepB vaccine. Anti-HBs: The presence of anti-HBs is generally interpreted as indicating recovery and immunity ...
[2]
Core Concepts - HBV Screening, Testing, and Diagnosis
Mar 13, 2023 · The presence of HBsAg indicates active infection, except in the situation whereby HBsAg is transiently present after receipt of a dose of ...
[3]
[PDF] Hepatitis B Surface Antigen (HBsAg) - CDC
Feb 24, 2011 · Hepatitis B surface antigen (HBsAg), derived from the viral envelope, is the first antigen to appear following infection and can be detected ...
[4]
Hepatitis B Surface Antigen Isoforms: Their Clinical Implications ...
The hepatitis B surface antigen (HBsAg) is a multifunctional glycoprotein composed of large (LHB), middle (MHB), and small (SHB) subunits.
[5]
Clinical Significance of Quantitative HBsAg Titres and its Correlation ...
Serum hepatitis B surface antigen (HBsAg) is a reliable biomarker of apparent hepatitis B virus infection. It is secreted as an subviral particles by infected ...Missing: definition | Show results with:definition
[6]
Screening for Viral Hepatitis - NCBI - NIH
The test for hepatitis B surface antigen detects the presence of HBV. A positive result means the person is currently infected and can pass the infection to ...Antigens and Antibodies · Hepatitis A Screening · Hepatitis B Screening<|control11|><|separator|>
[7]
HEPATITIS B VIRUS - Hepatitis Viruses - NCBI Bookshelf - NIH
Three different HBsAgs are synthesized: the large HBsAg (encoded by pre-S1, pre-S2 and S genes), the middle HBsAg (encoded by pre-S2 and S genes) and the major ...Missing: lipoprotein | Show results with:lipoprotein
[8]
Hepatitis B Virus Surface Antigen Assembly Function Persists ... - NIH
The particles are lipoprotein micelles, which contain 25% lipid. In these particles, HBsAg is believed to span the lipid four times, with four transmembrane ...
[9]
Subtyping of Hepatitis B Surface Antigen and Antibody by ...
Four major HBsAg subtypes have been well documented - adw, ayw, adr, and ayr - based on the presence of a group-specific antigen, which is com- mon to all ...
[10]
A meta-analysis on genetic variability of RT/HBsAg overlapping ...
Nov 7, 2019 · There are four major subtypes (Serotypes) of HBsAg; adw, ayw, adr, and ayr defined by a common “a” determinant and two mutually exclusive ...
[11]
Characterization of the lipid and protein organization in HBsAg viral ...
HBsAg particles are composed of host-derived lipids and virus-encoded glycoproteins [12], with a protein to lipid weight ratio of about 60:40 [14]. The HBsAg ...
[12]
Characterization of the Lipid and Protein Organization in HBsAg ...
Aug 7, 2025 · Like LDLs, the HBsAg particles were found to be composed of an ordered rigid lipid interface, probably organized as a phospholipid monolayer, ...
[13]
N-Glycosylation and N-Glycan Processing in HBV Biology and ...
Jun 4, 2020 · The two functional N-glycosylation sites are indicated: N4 in the preS2 region, occupied only in HBV-M; and N146 in the major hydrophilic ...
[14]
Modification of the Hepatitis B Virus Envelope Protein Glycosylation ...
The envelope proteins of hepatitis B virus (HBV) bear an N-linked glycosylation site at N146 within the immunodominant a-determinant in the antigenic loop (AGL) ...
[15]
A morphometric analysis of hepatitis B subviral particles shows no ...
Some of these particles are spherical, with a diameter of 22 nm, whereas others form large filaments of various lengths, between 80 and 400 nm.
[16]
Inherent symmetry and flexibility in hepatitis B virus subviral particles
Sep 12, 2024 · HBsAg structure. S-HBsAg protein is a 226–amino acid small-membrane protein but has an intrinsic ability to direct the formation of SVPs (17) ...Missing: lipoprotein | Show results with:lipoprotein
[17]
Assembly and Release of Hepatitis B Virus - PMC - NIH
S-HBsAg ... (Dane particles) containing spherical envelopes and virions with elongated appendages. Also shown are spherical and filamentous subviral particles ...
[18]
Hepatitis B virus S gene escape mutants - PMC - PubMed Central
A better understanding of the exact structural and physiochemical changes caused by mutations within the S gene is needed to determine which mutants modulate S ...
[19]
Immune-Escape Hepatitis B Virus Mutations Associated with Viral ...
Aug 24, 2019 · In most cases, HBsAg immune-escape mutants are due to missense mutations, often involving only one amino acid residue, rather than to ...
[20]
Ultra-deep sequencing reveals high prevalence and broad structural ...
This is typically due to mutations in the S gene (escape mutants), producing a modified HBsAg that is not recognized by some commercially available assays [21].
[21]
Sodium taurocholate cotransporting polypeptide is a functional ...
Nov 13, 2012 · We revealed that the receptor-binding region of pre-S1 specifically interacts with sodium taurocholate cotransporting polypeptide (NTCP), a multiple ...
[22]
An age-structured model of hepatitis B viral infection highlights the ...
Jan 24, 2022 · HBV infected cells produce a significant excess of non-infectious particles, such as subviral Dane particles (SVPs) that occur at 1000–100,000- ...
[23]
HBsAg, Subviral Particles, and Their Clearance in Establishing a ...
Jun 11, 2021 · ... (subviral particles or SVP) is commonly observed and is a commonly evolved mechanism for immune evasion. In hepatitis B virus (HBV) infection ...
[24]
Immune Mechanisms Underlying Hepatitis B Surface Antigen ...
High level of HBsAg is associated with the impairment of anti-HBV specific T and B cell immune function. Reducing the HBsAg level should promote the recovery of ...
[25]
Innate and adaptive immune escape mechanisms of hepatitis B virus
Serum HBsAg levels can be as high as 400 μg/mL in patients with CHB; thus, this phenomenon can play a key role in inhibiting HBV-specific immune responses.
[26]
The Functions of Hepatitis B Virus Encoding Proteins
Aug 12, 2021 · It reveals a mechanism that HBsAg evades the host innate immune response and hinders Th1 adaptive immunity by inhibiting IL-12 (22). Meanwhile, ...
[27]
Cholesterol requirement of hepatitis B surface antigen (HBsAg ...
Depletion of cholesterol from the membrane, leading to the destabilization of rafts (Nguyen and Taub, 2002), inhibits HBsAg secretion. Furthermore, the GPI- ...Regular Article · Results · Mevalonate Reverses The...<|control11|><|separator|>
[28]
Establishment and validation of an ELISA for the ... - PubMed
The use of two monoclonal antibodies produced "in house" specific for the small envelope protein S of the hepatitis B virus (HBV) resulted in the production of ...
[29]
Development of a sensitive enzyme-linked immunosorbent assay for ...
In this study, an ELISA assay has been developed for detection of HBsAg using two novel monoclonal antibodies (mAb) as capture layer and a polyclonal ...Missing: methods | Show results with:methods
[30]
[PDF] Determine HBsAg 2 (PQDx 0451-013-00) WHOPAR v 4.0.pdf
Oct 3, 2025 · Determine HBsAg 2 is a rapid immunochromatographic assay for the detection of HBsAg in ... test could detect a concentration of 0.1 IU/mL HBsAg.
[31]
Determine HBsAg 2 | Abbott Point of Care
WHO performance evaluations show that the analytical sensitivity of most rapid tests ranges from 2-10 IU/mL2 No rapid test for use with plasma, serum and ...Missing: ng/ | Show results with:ng/<|control11|><|separator|>
[32]
Highly sensitive and specific detection of hepatitis B virus DNA and ...
We developed a novel PCR-CRISPR method for highly sensitive and specific detection of HBV DNA and drug resistance mutations.
[33]
Molecular evaluation of hepatitis B virus infection and predominant ...
Jun 17, 2022 · The presence of HBsAg and HBcAb was determined by ELISA. Nested PCR, targeting S and pre-core regions of the HBV genome, followed by sequencing ...
[34]
[PDF] WHO/BS/2014.2241 - World Health Organization (WHO)
Oct 4, 2014 · Along with the WHO. HBV genotype panel for HBsAg assays (PEI product 6100/09) [12] and the WHO reference panel, HBsAg subtype adw2, genotype A ( ...
[35]
[PDF] Determine HBsAg 2 WHO reference number: PQDx 0451-013-00
Jul 14, 2023 · Determine HBsAg 2 is a rapid immunochromatographic assay for the detection of HBsAg in ... test could detect a concentration of 0.1 IU/mL HBsAg.
[36]
Diagnosis of hepatitis B - PMC - NIH
Sep 11, 2016 · HBsAg is the serological hallmark of HBV infection. After an acute exposure to HBV, HBsAg appears in serum within 1 to 10 weeks. Persistence of ...
[37]
Hepatitis B - StatPearls - NCBI Bookshelf
Jul 9, 2023 · The presence of HBsAg rarely persists beyond 6 months after infection and typically precedes detectable quantities of the corresponding antibody ...
[38]
The role of HBsAg levels in the current management of chronic HBV ...
HBsAg values of >100,000 IU/mL are suggestive for immune tolerance [13]. Patients in the immune tolerance phase usually show no or minimal histological ...
[39]
HBsAg level and hepatitis B viral load correlation with focus on ... - NIH
In most cases, a low level of HBsAg indicates a low HBV DNA level, whereas a high HBsAg level does not always correspond to a high viral load.
[40]
Screening and Testing for Hepatitis B Virus Infection - PubMed Central
Mar 10, 2023 · HBsAg: The presence of HBsAg indicates HBV infection, either acute or chronic, except when it might be transiently positive shortly after a dose ...
[41]
[PDF] Untitled - IRIS
Screening of donated blood for HBsAg has been mandatory since 1975. The ... In Japan, screening of blood donors for HBsAg was commenced in 1968. Since ...
[42]
AASLD 2018 Hepatitis B Guidance - PMC - PubMed Central
The presence of HBsAg establishes the diagnosis of hepatitis B. Chronic vs acute infection is defined by the presence of HBsAg for at least 6 months. The ...
[43]
Prevention of mother-to-child transmission of hepatitis B virus
Jul 27, 2020 · These guidelines provide evidence-based guidance on the use of peripartum antiviral prophylaxis in HBsAg-positive pregnant women for the prevention of mother- ...
[44]
HBsAg Loss as a Treatment Endpoint for Chronic HBV Infection - NIH
Functional cure of chronic hepatitis entails loss of HBsAg with undetectable HBV DNA that is sustained for at least 6 months following treatment discontinuation ...
[45]
https://www.who.int/publications/i/item/978-92-4-000270-8
[46]
[PDF] EASL Clinical Practice Guidelines on the management of hepatitis B ...
The guideline covers a wide spectrum of topics, ranging from diagnostics, patient evaluation and treatment indications to antiviral therapy options, monitoring ...
[47]
Chapter 10: Hepatitis B | Pink Book - CDC
May 9, 2024 · Serologic markers for HBV infection include HBsAg, antibody to HBsAg (anti-HBs) ... The first recombinant HepB vaccine, Recombivax HB, was ...
[48]
Recommendations of the Immunization Practices Advisory ... - CDC
When given in a three-dose series (10 ug per dose), recombinant HB vaccine induces protective antibodies (anti-HBs *) in over 95% of healthy adults 20-39 years ...
[49]
Hepatitis B vaccine development and implementation - PMC
The hepatitis B vaccine composed of HBsAg purified from the recombinant yeast cells potently induced anti-HBs response in mice, monkeys, and chimpanzees ...
[50]
Discontinuation of Nucleoside Analogues in Hepatitis B Virus Infection
PL Eradication of hepatitis B virus (HBV) is not an achievable endpoint with the current available anti-HBV therapeutic regimens. Even the closest outcome to a ...
[51]
Efficacy of Peginterferon alfa-2b in Nucleoside Analogue ...
Jul 25, 2021 · Only patients with PegIFNα-2b add-on therapy achieved HBsAg clearance (50.93%, 55/108) and HBsAg seroconversion (48.15%, 52/108) at week 48.
[52]
HBsAg clearance in chronic hepatitis B patients with add-on ... - NIH
PEG IFN and tenofovir add-on therapy was successful in achieving HBsAg clearance and seroconversion in 4.3% of the patients.
[53]
Hepatitis B vaccination: Are escape mutant viruses a matter of ... - NIH
This provides protection against all HBV genotypes (from A to H) and is responsible for the broad immunity afforded by hepatitis B vaccination. Thus, ...
[54]
Unexpected rise in the circulation of complex HBV variants enriched ...
Jun 8, 2023 · Specific HBsAg mutations are known to hamper HBsAg recognition by neutralizing antibodies thus challenging HBV-vaccination efficacy.<|control11|><|separator|>
[55]
Cross-Protection of Hepatitis B Vaccination among Different ...
Because available data show that current HBV-A2 vaccines are highly effective at preventing infections and clinical disease caused by all known HBV genotypes, ...
[56]
RNA Interference Therapy With ARC‐520 Results in Prolonged ...
We aimed to evaluate the depth of hepatitis B surface antigen (HBsAg) decline in response to multiple doses of ARC‐520 compared to placebo (PBO) in two ...
[57]
Advances with RNAi-Based Therapy for Hepatitis B Virus Infection
The ARC-520 siRNA was found to be well-tolerated with no serious adverse ... However, both ARC-520 and ARC-521 trials were discontinued following the ...<|control11|><|separator|>
[58]
[PDF] australia antigen and the biology of hepatitis b. - Nobel Prize
HEPATITIS B AS A POLYMORPHISM. The original discovery of hepatitis B resulted from the study of serum antigen polymorphisms. ... Australia antigen: The history of ...
[59]
Medical Virology of Hepatitis B: how it began and where we are now
The first clue in unraveling this mystery was the discovery of an enigmatic serum protein named Australia antigen 50 years ago by Baruch Blumberg. Some years ...
[60]
Australia antigen: large-scale purification from human serum and ...
A three-step procedure involving isopycnic banding of the particle in CsCl density gradients and rate-zonal centrifugation on sucrose gradients resulted in a ...Missing: early | Show results with:early
[61]
Synthesis and assembly of hepatitis B virus surface antigen particles ...
Jul 22, 1982 · The surface antigen of hepatitis B virus (HBsAg) has been synthesized in the yeast Saccharomyces cerevisiae by using an expression vector.
[62]
Vaccine-induced escape mutant of hepatitis B virus - ScienceDirect
Aug 11, 1990 · The virus from this patient is an escape mutant with a different sequence from that of the isolate from the mother.
[63]
Vaccine-induced escape mutant of hepatitis B virus - PubMed
The virus from this patient is an escape mutant with a different sequence from that of the isolate from the mother.Missing: G145R | Show results with:G145R
[64]
Persistence of cccDNA during the natural history of chronic hepatitis ...
The aim of this study was to develop a sensitive and specific assay for quantifying cccDNA in biopsy samples from chronic hepatitis B patients during different ...Missing: Hepatology | Show results with:Hepatology